Plasmapheresis may not Reduce Organ Failure among patients with hypertriglyceridemia associated pancreatitis
An Original Investigation on Gastroenterology and Hepatology published on June 28, 2023, in JAMA Network Open entitled "Early Plasmapheresis Among Patients With Hypertriglyceridemia–Associated Acute Pancreatitis" by lead author Cao et al. have mentioned that plasmapheresis does not confer any clinical benefit in managing hypertriglyceridemia-associated acute pancreatitis or HTG-AP and is associated with potential complications.
In this study, researchers found no association between plasmapheresis and the incidence and duration of organ failure. Plasmapheresis may not decrease triglyceride levels more efficiently than conventional medical therapy. These findings of the present study are comparable with those conducted by Chen et al. and Miyamoto et al.
It is already known that there is an increasing incidence of hypertriglyceridemia–associated acute pancreatitis (HTG-AP). Plasmapheresis is theoretically effective in removing triglyceride from plasma, but there needs to be more clarity on whether it has clinical benefits.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.